Transplantační medicína

Primer estudio de evidencia del mundo real que evalúa la efectividad de dupilumab en pacientes con asma.

Syncytialny wirus układu oddechowego (RSV) stanowi główną przyczynę zakażeń dolnych dróg oddechowych u niemowląt i małych dzieci, prowadząc rocznie do około 3,2 miliona hospitalizacji i nawet 200 000 zgonów na całym świecie u dzieci poniżej 5. roku życia.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® is available in two prefilled pens. See how Toujeo® is administrated In six simple steps and watch instructional video.

Toujeo is a 2nd generation, long-acting insulin analog containing insulin glargine 300 units/mL. Toujeo® lowers blood glucose levels evenly over a long period of time. It therefore only needs to be administered once a day.

Join Professor Yung Chee Fu as he presents the compelling clinical evidence behind nirsevimab (Beyfortus), a breakthrough single-dose solution for RSV protection in all infants. Through comprehensive trial data, Prof. Yung demonstrates nirsevimab's remarkable 70-86% efficacy in preventing RSV-related hospitalizations across all infant populations. The presentation highlights how Nirsevimab provides extended protection beyond five months, making it particularly valuable for Singapore's year-round RSV season, while maintaining an excellent safety profile across all gestational ages.

Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.

Join Professor Yeo Kee Thai for an in-depth exploration of Respiratory Syncytial Virus (RSV) burden in Singapore and its significant impact on our healthcare system. Through evidence-based insights, he demonstrates how RSV affects not only premature infants but also healthy full-term babies, with 53% of PICU admissions being previously healthy term infants. His presentation addresses Singapore's unique year-round RSV activity pattern and its implications for infant protection strategies.